ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,039.71
-0.12%
US Tech 100
20,602.40
-0.04%
다우존스 지수
44,689.17
-0.21%
Bitcoin
94,961.48
-0.94%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. TransMedics Group Inc (TMDX)

  7. TransMedics Group Inc (TMDX) 뉴스

TransMedics Group Inc

TransMedics Group Inc (TMDX)

NASDAQ
72.34
-12.80
( -15.03% )
업데이트: 02:10:55
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

TMDX 뉴스

공식 뉴스 전용

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
20 시간 전
TMDX (-15.03%)

Form 8-K - Current report
Edgar (US Regulatory)
20 시간 전
TMDX (-15.03%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 11월 2024
TMDX (-15.03%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
06 11월 2024
TMDX (-15.03%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
30 10월 2024
TMDX (-15.03%)

Form 8-K - Current report
Edgar (US Regulatory)
29 10월 2024
TMDX (-15.03%)

Form 8-K - Current report
Edgar (US Regulatory)
12 9월 2024
TMDX (-15.03%)

TMDX Discussion

게시물 보기
Monksdream Monksdream 7 월 전
TMDX new 52+ week high
👍️0
Monksdream Monksdream 9 월 전
TMDX 10Q
👍️0
make it happen make it happen 1 년 전
Should touch $50 net lose widens, and has a 40% day. The structure shows over 100% ownership which technically should be illegal. How can there be over 100%? Imho mean institutions and whomever will be selling for a 40%ish profit overnight.
👍️0
crudeoil24 crudeoil24 4 년 전
TransMedics Late Tuesday Announced FDA Advisory Committee Panel Voted 12 To 5 That Benefits Of OCS Heart System Outweigh Risks
6:58 am ET April 7, 2021 (Benzinga) Print
TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after the review of TransMedics' clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol ("CAP") results, as well as the OCS Heart PROCEED II trial, the Circulatory Systems Device Advisory Panel convened by the U.S. Food and Drug Administration ("FDA") has issued a favorable vote in support of approval of the OCS Heart System to the FDA's Office of Health Technology 2 (Cardiovascular Devices). The panel voted 12 to 5, with 1 abstaining, that the benefits of the OCS Heart System outweigh its risks. The panel voted 10 to 6, with 2 abstaining, that there is reasonable assurance that the OCS Heart System is effective. The panel voted 9 to 7, with 2 abstaining, that there is reasonable assurance of the OCS Heart System's safety.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
👍️0
crudeoil24 crudeoil24 4 년 전
Transmedics group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Lung INSPIRE Trial, OCS Lung Expand Trial, OCs Heart EXPAND and PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. It is also focused on developing additional OCS products for kidney transplantation.
👍️0

최근 히스토리

NASDAQ
TMDX
TransMedics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유